牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-20-004215 Act: 34 Size: 70 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-074877 Act: 34 Size: 102 KB 网页链接
$灿菲特生物制药(CANF)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001213900-20-014766 Act: 33 Size: 656 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-014760 Act: 34 Size: 526 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-014566 Act: 34 Size: 34 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-014449 Act: 34 Size: 24 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-014056 Act: 34 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001213900-20-013766 Act: 33 Size: 1 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-013762 Act: 34 Size: 4 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-013186 Act: 34 Size: 33 KB 网页链接